Venetoclax in adult acute myeloid leukemia

Mengci Hu; Wenzhe Li; Youshan Zhang; Caixia Liang; Jie Tan; Ya Wang

doi:10.1016/j.biopha.2023.115820

Venetoclax in adult acute myeloid leukemia

Biomed Pharmacother. 2023 Dec:168:115820. doi: 10.1016/j.biopha.2023.115820. Epub 2023 Nov 6.

Authors

Mengci Hu¹, Wenzhe Li², Youshan Zhang¹, Caixia Liang¹, Jie Tan³, Ya Wang⁴

Affiliations

¹ Department of Hematology, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei, China.
² Department of Endocrinology, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei, China.
³ Department of Hematology, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei, China. Electronic address: tanjie@yangtzeu.edu.cn.
⁴ Department of Endocrinology, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei, China; Department of Hubei Provincial Clinical Research Center for Personalized Diagnosis and Treatment of Cancer, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei, China. Electronic address: wangya@yangtzeu.edu.cn.

PMID: 37925935
DOI: 10.1016/j.biopha.2023.115820

Abstract

Venetoclax is a potent inhibitor that specifically targets B-cell lymphoma-2 (BCL-2), which has been demonstrated to be effective in preclinical studies utilizing acute myeloid leukemia (AML) cell lines and xenograft models. Significant antileukemic activity was also observed in clinical trials, both as a monotherapy and in combination with other drugs. This novel therapeutic approach has revolutionized the treatment prospects for AML patients with unfavorable prognoses and those who are unable to tolerate intensive chemotherapy. Nevertheless, further investigations are required to establish the optimal dosing, sequencing, and combinational strategies of venetoclax for AML treatments. Additionally, identifying biomarkers is crucial for predicting response and resistance to this targeted intervention. In this review, we provide an overview of venetoclax-based therapy for AML and explore potential avenues for future research.

Keywords: Acute myeloid leukemia; Combinatorial regimens; Venetoclax.

Publication types

Review

MeSH terms

Adult
Apoptosis
Bridged Bicyclo Compounds, Heterocyclic / pharmacology
Bridged Bicyclo Compounds, Heterocyclic / therapeutic use
Humans
Leukemia, Myeloid, Acute* / drug therapy
Leukemia, Myeloid, Acute* / metabolism
Proto-Oncogene Proteins c-bcl-2* / metabolism

Substances

venetoclax
Proto-Oncogene Proteins c-bcl-2
Bridged Bicyclo Compounds, Heterocyclic